SRX 0.00% $33.55 sirtex medical limited

sirtex in news again good acro results coming

  1. 2,773 Posts.


    Doctors
    Other Staff
    Presentations and Talks
    Who Makes Up The Radiation Team
    Treatment Details
    Steps Leading to Actual Treatment
    Taking Care of Yourself During Radiation Therapy
    Common Terminology
    Directions
    Insurance Information
    Cancer and Radiation Therapy Links
    Educational Videos
    3-D Conformal Treatment (3DCRT)
    Intensity Modulated Radiotherapy (IMRT)
    Brachytherapy (Implant) Programs
    General Information
    MammoSite®
    Microsphere Therapy
    General Information
    Infusion of Microspheres to Treat Liver Tumors
    General Information
    MammoSite® Frequently Asked Questions
    Milestones in Internal Radiation Treatment for Bre
    MammoSite RTS: Broadening Access to Breast Conserv
    Presentations
    Breast Cancer
    Liver Cancer
    Prostate Cancer




    | Login | Search


    Home

    Specialties

    Services

    For Patients

    Location

    Staff

    In The News

    Contact Us







    Our Patients Say...
    The care given to me by the therapists was excellent! The warmth and compassion shown to me by the entire office made my experience with the treatment a breeze! Thanks so much.



    In The News » Sirtex Sponsors Educational Breakfast Lecture
    Print this page


    Sirtex Sponsors Educational Breakfast Lecture at the 2008 American College of Radiation Oncology Annual Meeting
    Lecture to Highlight the Latest Clinical Research Results Regarding the Use of Radioembolization for the Treatment of Liver Tumors

    WILMINGTON, Mass. - Sirtex, a leading developer of targeted and innovative cancer therapies, will sponsor a breakfast lecture at the 18th Annual American College of Radiation Oncology (ACRO) meeting to be held February 21-23 in Miami, Fla. The breakfast lecture, titled "Radioembolization Therapy for the Treatment of Liver Tumors: Latest Clinical Results," will take place on Thursday, February 21 at 7:30 a.m. in the Trianon Room at the Intercontinental Hotel.

    The lecture, hosted by Andrew S. Kennedy, M.D., F.A.C.R.O., co-medical director of Wake Radiology Oncology in Cary, N.C., is designed to update physicians on the latest clinical results regarding the use of microsphere therapy, including SIR-Spheres(R) microspheres, in the treatment of metastatic liver tumors. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved radioactive microspheres for treatment of metastatic liver tumors.(1)

    "Sirtex is pleased to once again participate in this year's ACRO meeting," says Scott Richardson, director of sales for Sirtex. "There is a tremendous amount of research taking place involving SIR-Spheres microspheres, and meetings such as this provide a forum to distribute that information to physicians to help advance the role microsphere therapy can play in treating liver tumors."

    The lecture is free and open to members of the medical community attending the ACRO meeting. No advanced reservations are required.

    (1) Sirtex Medical Inc.'s SIR-Spheres(R) microspheres are indicated for the treatment of non-resectable metastatic colorectal cancer in combination with intra-arterial FUDR chemotherapy. Information regarding other disease states or agents in combination with this device that is presented in peer-reviewed literature is different from the approved USA labeling for SIR-Spheres.

    About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres

    Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumors. In a minimally-invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

    Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

    SIRT using SIR-Spheres microspheres is approved for use in Australia, New Zealand, the United States of America (FDA approval), European Union (CE Mark), Hong Kong, Malaysia, Singapore, Thailand, Israel and India. SIRT is available in 140 treatment centers around the world, and more than 6500 patients have been treated to date.

    Approximately 90 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 86 medical centers. For more information, visit www.sirtex.com.

    (R) SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

    For Sirtex Andrea Moody, 919-457-0743 [email protected]








    © 2008 | Terms Of Use | Privacy Statement | Site by Spence Hackney Design




 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.